Attractive Eli Lilly (LLY) Credit Profile
Eli Lilly (LLY) is a leading research-driven pharmaceutical company with a strong presence in the central nervous system, diabetes and obesity, and oncology markets. As equity markets adjust to recession concerns, we frequently receive inquiries from clients seeking stable market players with strong credit profiles, impressive margins of safety, and low leverage. In our view, LLY stands out as a compelling long-term investment candidate.
Our equity team has rated LLY as a Buy (Outperform) due to its significant upside potential across a broad portfolio.
We believe Eli Lilly is well-positioned to maintain a dominant market share in key categories for the foreseeable future, supported by competitive advantages that reinforce its leadership. We maintain the same view on LLY bonds:
Keep reading with a 7-day free trial
Subscribe to Yaru Investments Substack to keep reading this post and get 7 days of free access to the full post archives.